IJARSCT
ISSN: 2581-9429
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Stem Cell Therapy on Diabetes Mellitus

Mr. Rathod Sahil Ramesh, Prof. Priyanka Jadhao, Dr. Mahesh Pandurang Bhosale
Dharmaraj Shaikshanik Pratisthan College of Pharmacy, Walki, Ahilyanagar

Abstract: *Diabetes mellitus is a rapidly growing global health concern that significantly impacts public health systems worldwide. In recent years, stem cell–based therapies have gained attention due to their regenerative potential and ability to restore damaged tissues, offering a promising approach for diabetes treatment. This review discusses recent progress, future prospects, and existing challenges associated with the application of stem cell therapy in diabetes management. Particular emphasis is placed on induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), the development of pancreatic islet organoids, and advances toward personalized treatment strategies. The paper also examines outcomes from clinical trials to assess the safety and effectiveness of stem cell–based interventions for both type 1 and type 2 diabetes. Despite encouraging results, several limitations remain, including concerns related to safety, transplantation success rates, ethical considerations, and immune rejection. The review concludes by highlighting future directions, such as integrating stem cell therapy with conventional treatments and advancing personalized medicine, which together present new possibilities for improved diabetes care.*

Keywords: Diabetes mellitus, Stem cell therapy, Induced pluripotent stem cells (iPSCs), Embryonic stem cells, (ESCs).

I. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder characterized by the body's inability to regulate blood glucose levels effectively. Glucose serves as the main source of energy for body cells, and its proper utilization depends on insulin, a hormone secreted by the pancreas. Insulin enables glucose to move from the bloodstream into cells, where it is used for energy production. When insulin secretion is insufficient or when the body becomes resistant to its action, glucose accumulates in the blood, resulting in elevated blood sugar levels. Persistent hyperglycemia can lead to serious long-term complications, including cardiovascular disease, kidney damage, vision impairment, nerve disorders, and other systemic problems.

Diabetes is generally classified into three major types:

Diabetes mellitus is a chronic metabolic disorder characterized by impaired regulation of blood glucose levels due to defects in insulin production, insulin action, or both. It is broadly classified into two major types:

Type 1 diabetes and Type 2 diabetes, each differing in cause, progression, and management.

Type 1

diabetes is an autoimmune condition in which the body's immune system mistakenly identifies the insulin-producing beta cells of the pancreas as foreign and destroys them. As a result, the pancreas is unable to produce sufficient insulin, a hormone essential for regulating blood glucose levels. This form of diabetes typically develops during childhood or early adulthood, although it can occur at any age. Individuals with Type 1 diabetes are dependent on lifelong insulin therapy to survive, as their bodies cannot produce insulin naturally.

In contrast,

Type 2

diabetes develops when the body becomes resistant to the effects of insulin or when the pancreas fails to produce enough insulin to meet the body's needs. It is the most prevalent form of diabetes worldwide and is strongly associated with lifestyle-related factors such as obesity, unhealthy dietary habits, physical inactivity, and genetic predisposition. Unlike Type 1 diabetes, Type 2 diabetes often develops gradually and may initially be managed through lifestyle modifications, oral medications, and, in some cases, insulin therapy.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

In recent years, stem cell research has gained significant attention due to its potential to revolutionize the treatment of various chronic and degenerative diseases, including diabetes. Stem cells are unique cells with the remarkable ability to develop into many different types of specialized cells in the human body. This makes them highly valuable for regenerative medicine, where the goal is to repair, replace, or restore damaged tissues and organs.

For a cell to be classified as a stem cell, it must possess two fundamental characteristics. The first is the capacity for self-renewal, meaning it can divide repeatedly to produce identical copies of itself over long periods. Although this property is similar to that observed in cancer cells, stem cell division is tightly controlled and regulated. The second defining feature is pluripotency or multipotency—the ability of stem cells to differentiate into specialized cell types that perform specific functions essential for normal bodily processes.

The term "stem cell" encompasses a diverse range of cell types. Traditionally, stem cells were categorized as either embryonic stem cells or adult stem cells based on their developmental origin. Embryonic stem cells are derived from early-stage embryos and have the ability to differentiate into nearly all cell types in the body. Adult stem cells, also known as somatic stem cells, are found in mature tissues and typically give rise to a limited range of cell types related to their tissue of origin. However, advances in scientific research have led to the discovery of induced pluripotent stem cells (iPSCs), which are adult cells that have been genetically reprogrammed to behave like embryonic stem cells. This breakthrough has expanded the possibilities of stem cell research while reducing ethical concerns associated with embryonic stem cells.

Stem cell therapy represents a highly promising and innovative approach for the treatment of diabetes, particularly Type 1 diabetes, where the loss of insulin-producing beta cells is the primary cause of the disease. Researchers are actively exploring ways to use stem cells to generate functional pancreatic beta cells that can be transplanted into patients. The ultimate goal of this therapy is not merely to manage blood glucose levels but to restore the body's natural ability to produce insulin, potentially offering a long-term or permanent solution to the disease.

Although stem cell therapy for diabetes is still in the experimental stage and largely limited to clinical trials, the results so far have been encouraging. Numerous studies conducted in animal models have demonstrated that stem cell–derived insulin-producing cells can improve glucose control and reduce dependence on external insulin. However, translating these findings into safe and effective treatments for humans presents significant challenges. These include determining the most suitable type of stem cells, optimizing transplantation methods, preventing immune rejection, and ensuring long-term functionality and safety of the transplanted cells.

Ethical considerations, technical complexities, and the high cost of treatment have also limited the widespread application of stem cell therapy in human patients. As a result, only a small number of stem cell–based approaches have progressed to advanced clinical trials. Despite these challenges, ongoing research continues to refine these techniques and address unanswered questions regarding long-term outcomes and potential side effects.

This review aims to critically analyze existing studies on stem cell therapy for both Type 1 and Type 2 diabetes, with a particular focus on evaluating safety and therapeutic effectiveness. In this context, safety refers to the absence of serious adverse effects, while effectiveness is measured by improvements in insulin production, glucose regulation, and overall metabolic control. The findings of such studies may provide valuable insights for future research and assist healthcare professionals and patients in understanding the potential role of stem cell therapy in diabetes management.:

Pathophysiology of Diabetes Mellitus

Diabetes mellitus (DM) is a heterogeneous metabolic disorder with a complex and multifactorial pathophysiology. It is characterized by chronic hyperglycemia resulting from abnormalities in insulin secretion, insulin action, or a combination of both. Because diabetes presents with diverse clinical features and develops through multiple biological pathways, any classification system is, to some extent, arbitrary. Nevertheless, classification remains essential for understanding disease mechanisms, guiding clinical management, and predicting long-term outcomes. The current classification system categorizes diabetes based on both its underlying cause and disease progression, enabling healthcare professionals to tailor treatment strategies more effectively.

According to this widely accepted system, diabetes mellitus is broadly divided into four major categories: Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and diabetes associated with

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

specific genetic defects, diseases, or medical conditions. Each type differs significantly in etiology, pathogenesis, and clinical management.

Type 1 Diabetes Mellitus

Type 1 diabetes mellitus is an autoimmune disorder that results from the immune-mediated destruction of insulin-producing beta cells in the pancreatic islets of Langerhans. This destructive process is driven by a complex interaction between genetic susceptibility and environmental triggers, such as viral infections or other external factors. In susceptible individuals, autoreactive lymphocytes mistakenly identify pancreatic beta cells as foreign and initiate an immune response that progressively damages and ultimately eliminates these cells.

As beta-cell mass declines, insulin production becomes insufficient to maintain normal glucose homeostasis. Consequently, individuals with T1DM develop absolute insulin deficiency and require lifelong exogenous insulin therapy to survive. Without insulin replacement, patients are at high risk of developing acute complications such as diabetic ketoacidosis, which can be life-threatening if not promptly treated.

Type 1 diabetes affects approximately one in every 300 individuals and has been increasing in incidence globally at an estimated annual rate of around 3%. Despite extensive research, the precise mechanisms underlying the initiation and progression of the autoimmune response remain incompletely understood. The unpredictable onset and lifelong dependence on insulin therapy make the management of T1DM particularly challenging for patients, families, and caregivers.

In many regions, a shortage of pediatric endocrinologists has resulted in general pediatricians and other healthcare providers assuming responsibility for diabetes care, further emphasizing the need for improved education and standardized management approaches. Current research efforts focus on understanding immune regulation, preserving residual beta-cell function, and developing novel therapies such as immunomodulation, beta-cell replacement, and stem cell–based interventions.

Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is the most prevalent form of diabetes and arises from a combination of insulin resistance and progressive beta-cell dysfunction. Unlike T1DM, Type 2 diabetes is not caused by autoimmune destruction but is strongly associated with lifestyle factors such as obesity, sedentary behavior, poor dietary habits, and genetic predisposition.

The pathophysiology of T2DM begins with the development of insulin resistance, a condition in which target tissues—particularly skeletal muscle, adipose tissue, and the liver—fail to respond adequately to normal circulating levels of insulin. As a result, glucose uptake by peripheral tissues is impaired, and hepatic glucose production remains elevated, leading to rising blood glucose levels.

In response to insulin resistance, the pancreas initially compensates by increasing insulin secretion. During this early phase, blood glucose levels may remain within the normal range. However, prolonged overproduction of insulin places excessive stress on pancreatic beta cells. Over time, these cells undergo functional exhaustion and structural damage, leading to a gradual decline in insulin secretion.

As beta-cell function deteriorates, the compensatory mechanism fails, resulting in relative insulin deficiency and persistent hyperglycemia. This progression explains why Type 2 diabetes often develops gradually and may remain undiagnosed for years. Chronic hyperglycemia in T2DM contributes to long-term complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy.

Clinical and Research Implications

Understanding the distinct pathophysiological mechanisms underlying different forms of diabetes is crucial for effective disease management and the development of targeted therapies. While insulin replacement remains essential for individuals with T1DM, treatment strategies for T2DM often focus on improving insulin sensitivity, preserving beta-cell function, and modifying lifestyle factors.

Ongoing research continues to explore novel therapeutic approaches aimed at preventing disease progression, restoring beta-cell function, and achieving long-term glycemic control. Advances in immunotherapy, regenerative medicine, and precision medicine hold promise for transforming the future management of diabetes mellitus.

Concept of Stem Cell Therapy

Stem cell therapy is a rapidly advancing field within regenerative medicine that aims to restore, replace, or repair damaged tissues and organs by utilizing the unique biological properties of stem cells. Stem cells are distinct from other cells in the body because they possess two defining characteristics that make them especially valuable for therapeutic applications. First, they have the ability for self-renewal, meaning they can divide and produce identical copies of themselves over extended periods. This capacity allows stem cells to maintain their population and continuously supply new cells for tissue maintenance and repair. Second, stem cells possess the potential to differentiate into specialized cell types with specific structural and functional roles, enabling them to contribute to the formation of diverse tissues throughout the body.

Stem cells are present in nearly all tissues of the human body and play a critical role in normal growth, tissue homeostasis, and wound healing. When injury or degeneration occurs, resident stem cells are activated and differentiate into the cell types needed to restore damaged structures. Depending on their origin and biological potential, stem cells can give rise to a wide range of tissues, including blood, cardiac muscle, neural tissue, skeletal muscle, bone, cartilage, and connective tissue.

Stem cells are broadly classified into several categories based on their developmental origin and differentiation potential. Among these, embryonic stem cells are considered the most versatile. They are derived from early-stage embryos, specifically from blastocysts that are approximately three to five days old and consist of around 150 cells. Embryonic stem cells are pluripotent, meaning they have the ability to develop into nearly all cell types that form the human body. In addition to their extensive differentiation capacity, these cells can undergo unlimited self-renewal under appropriate laboratory conditions. Because of these properties, embryonic stem cells hold significant promise for repairing or replacing damaged tissues and organs affected by disease or injury.

In contrast, adult stem cells—also referred to as somatic stem cells—are found in various tissues throughout the body, including bone marrow, adipose tissue, skin, and skeletal muscle. Their primary role is to maintain and repair the tissues in which they reside. Compared to embryonic stem cells, adult stem cells have a more restricted differentiation potential and typically give rise to cell types related to their tissue of origin. Despite this limitation, adult stem cells have been successfully used in several clinical applications, such as bone marrow transplantation for the treatment of blood-related disorders.

A major breakthrough in stem cell research has been the development of induced pluripotent stem cells (iPSCs). This technique involves genetically reprogramming fully differentiated adult cells, such as skin fibroblasts or connective tissue cells, to revert them to a pluripotent state similar to that of embryonic stem cells. Induced pluripotent stem cells exhibit the capacity for self-renewal and can differentiate into a wide variety of specialized cell types. One of the key advantages of iPSCs is their potential to reduce immune rejection, as the cells can be derived from the patient's own tissues. However, concerns remain regarding the long-term safety of these genetically modified cells, including the risk of abnormal growth or tumor formation, and ongoing research aims to address these challenges.

Experimental studies have demonstrated the therapeutic potential of stem cell–based interventions in various disease models. For example, researchers have successfully reprogrammed connective tissue cells into functional cardiac cells, and animal models of heart failure treated with these cells have shown improved cardiac function and increased survival rates. Such findings highlight the broad regenerative potential of stem cell therapy beyond a single disease area.

In addition to embryonic and adult stem cells, researchers have identified valuable stem cell populations in umbilical cord blood and amniotic fluid. Umbilical cord blood is a rich source of hematopoietic stem cells and has been widely used in the treatment of blood and immune disorders. Amniotic fluid, which surrounds and protects the developing fetus within the uterus, also contains stem cells with significant differentiation potential. These cells can be obtained through procedures such as amniocentesis and have demonstrated the ability to differentiate into multiple specialized cell types, making them a promising and ethically acceptable source for future therapeutic applications.

Overall, stem cell therapy represents a transformative approach in modern medicine, offering the possibility of treating previously incurable diseases through tissue regeneration and functional restoration. Although significant progress has been made, further research is required to optimize cell sources, ensure safety, and establish standardized protocols before widespread clinical application can be achieved.

Types of Stem Cells Used in Diabetes Therapy

Several types of stem cells are being explored for the treatment of diabetes mellitus, particularly for restoring insulin production and improving glucose regulation. The most commonly studied stem cells include induced pluripotent stem cells, mesenchymal stem cells, and embryonic stem cells.

1. Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells represent a promising approach for diabetes treatment, especially Type 1 diabetes. iPSCs are generated by genetically reprogramming adult somatic cells, such as skin or blood cells, into a pluripotent state. These cells can then be differentiated into insulin-producing pancreatic β-like cells. Once transplanted, usually into the liver, iPSC-derived β-cells can engraft, survive, and respond to glucose levels by secreting insulin.

The major advantage of iPSC therapy is the ability to create patient-specific β-cells, which significantly reduces the risk of immune rejection. Animal studies have shown increased insulin secretion and long-term maintenance of normal blood glucose levels. Additionally, iPSCs provide valuable platforms for disease modeling, drug testing, and genome editing to enhance β-cell survival. However, challenges such as ensuring long-term safety, preventing abnormal cell growth, and standardizing production methods must be addressed before widespread clinical use.

2. Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells are adult stem cells known for their regenerative, anti-inflammatory, and immunomodulatory properties. MSC therapy has shown encouraging results in both Type 1 and Type 2 diabetes by supporting pancreatic β-cell survival, repairing damaged islets, and improving insulin sensitivity. These cells can migrate to injured pancreatic tissue and modulate immune responses that contribute to β-cell destruction.

Clinical studies have reported significant improvements in glycemic control, including reductions in HbA1c and fasting blood glucose levels, along with increased endogenous insulin production. MSC therapy has also been associated with reduced insulin requirements and a favorable safety profile, making it a promising therapeutic option for diabetes management.

3. Embryonic Stem Cells (ESCs)

Embryonic stem cells are pluripotent cells derived from early-stage embryos and have the ability to differentiate into all cell types, including pancreatic β-cells. Due to their high differentiation potential, ESCs are valuable for generating insulin-producing cells for diabetes therapy. However, ethical concerns, immune rejection, and safety issues such as tumor formation have limited their clinical application. Ongoing research aims to overcome these barriers and harness their regenerative potential safely.

Potential and Challenges of Mesenchymal Stem Cell Therapy

Mesenchymal stem cells (MSCs) derived from sources such as human umbilical cord tissue and adipose tissue have shown considerable promise in diabetes therapy due to their high regenerative capacity and immunomodulatory effects. These sources offer advantages in terms of cell availability, ease of collection, and therapeutic potency. Clinical findings indicate improved glycemic control and enhanced endogenous insulin production in both Type 1 and Type 2 diabetes. However, further research is required to optimize MSC homing to pancreatic tissue, improve post-transplant cell survival, standardize treatment protocols, and evaluate long-term safety and efficacy. Ongoing studies aim to refine these parameters to maximize clinical benefit while ensuring patient safety.

Embryonic Stem Cell Therapy for Diabetes

Embryonic stem cell (ESC) therapy for diabetes is based on the use of pluripotent stem cells derived from early-stage embryos, which have the capacity to differentiate into insulin-producing pancreatic β-cells. These cells can replace the damaged or dysfunctional β-cells responsible for impaired insulin secretion in diabetes. Through controlled laboratory

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

differentiation, ESCs are guided to develop into mature, glucose-responsive β-like cells that mimic the natural function of pancreatic islets.

Once transplanted—commonly into sites such as the liver—these cells can engraft, integrate with host vasculature, and secrete insulin in response to blood glucose fluctuations, potentially reducing or eliminating the need for external insulin therapy. Despite its regenerative potential, ESC therapy faces significant challenges, including immune rejection, the need for immunosuppression or cell encapsulation strategies, and safety concerns such as teratoma formation from undifferentiated cells.

Current research demonstrates encouraging early results, with some studies reporting improved glycemic control and reduced insulin dependence. However, large-scale clinical trials are necessary to establish consistent efficacy, long-term safety, and standardized protocols. Ethical and regulatory concerns related to embryonic cell sources further complicate clinical translation. Addressing immune compatibility, ensuring stable engraftment, minimizing tumor risk, and scaling the production of fully differentiated β-cells remain key priorities before widespread clinical adoption can be achieved.

Other Stem Cells Used in Diabetes Therapy

In addition to widely studied stem cell types such as induced pluripotent stem cells, mesenchymal stem cells, and embryonic stem cells, several other stem and immune cell populations have emerged as promising candidates for diabetes therapy. These include pancreatic stem cells, umbilical cord blood–derived stem cells, and thymic regulatory T cells. Each of these cell types offers unique therapeutic mechanisms aimed at restoring insulin production, improving glycemic control, or modulating the autoimmune processes underlying diabetes.

1. Pancreatic Stem Cells

Pancreatic stem cells are specialized progenitor cells located within the pancreas or generated through laboratory-based differentiation techniques. These cells possess the potential to differentiate into various pancreatic cell lineages, including insulin-producing β-cells. Due to their tissue-specific origin, pancreatic stem cells are considered a highly relevant and physiologically compatible source for diabetes treatment.

Within the pancreas, these progenitor cells are commonly found near pancreatic ducts and are believed to contribute to β-cell regeneration through a process known as islet neogenesis. Under certain biological conditions, other pancreatic cells, such as acinar cells, may also undergo transdifferentiation into insulin-secreting β-like cells. This inherent regenerative capacity highlights the pancreas as a valuable reservoir for cellular repair.

Recent advances in regenerative medicine have focused on improving the efficiency, safety, and scalability of generating pancreatic progenitor cells from pluripotent stem cells or directly from patient-derived tissues. These strategies aim to overcome limitations associated with donor islet scarcity and immune incompatibility. By producing patient-specific or immunologically matched β-cells, pancreatic stem cell–based therapies hold the potential to restore endogenous insulin secretion, reduce dependence on lifelong insulin therapy, and minimize the need for chronic immunosuppression. Ongoing research continues to refine differentiation protocols and transplantation methods to enhance long-term graft survival and functional stability.

2. Umbilical Cord Blood Stem Cells

Umbilical cord blood stem cells, particularly mesenchymal stem cells derived from cord blood, have gained increasing attention as a therapeutic option for diabetes. These cells exhibit strong regenerative, anti-inflammatory, and immunomodulatory properties, making them suitable for both Type 1 and Type 2 diabetes management. Their ability to regulate immune responses is especially beneficial in Type 1 diabetes, where autoimmune destruction of β-cells plays a central role.

Clinical studies have demonstrated that intravenous infusion of umbilical cord blood–derived MSCs can lead to significant improvements in glycemic control. In patients with Type 2 diabetes, treatment has been associated with reductions in HbA1c levels, improved fasting glucose, and increased time spent within the normal glucose range. In individuals with Type 1 diabetes, cord blood stem cell therapy has shown potential to reduce insulin requirements and enhance overall quality of life by preserving residual β-cell function.

One of the major advantages of umbilical cord blood stem cells is their favorable safety profile. These cells exhibit low immunogenicity, reducing the risk of immune rejection, and have a minimal tendency to form tumors. Furthermore, they

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

typically require little to no immunosuppressive therapy, making them a safer alternative compared to other stem cell sources. Beyond glycemic control, umbilical cord blood stem cells may also contribute to the prevention or treatment of diabetes-related complications, including diabetic neuropathy and nephropathy, by promoting tissue repair and reducing inflammation. Despite promising outcomes, large-scale, well-controlled clinical trials are necessary to establish standardized treatment protocols and confirm long-term efficacy.

3. Thymic Regulatory T Cells

Thymic regulatory T cell (Treg) therapy represents an emerging immunotherapeutic approach for Type 1 diabetes that focuses on addressing the autoimmune basis of the disease rather than directly replacing insulin-producing cells. In T1D, a failure of immune tolerance allows autoreactive T cells to attack and destroy pancreatic β-cells. This pathological process is often associated with a deficiency or dysfunction of regulatory T cells, which normally suppress excessive immune responses and maintain self-tolerance.

Thymic Tregs play a crucial role in controlling autoimmunity by inhibiting the activation and proliferation of autoreactive immune cells. Therapeutic strategies involving the expansion, enhancement, or reinfusion of Tregs aim to restore immune balance and protect remaining β-cells from further destruction. By re-establishing immunological tolerance, Treg therapy has the potential to slow or halt disease progression, particularly when administered during the early stages of Type 1 diabetes.

Current research is exploring methods to increase the stability, specificity, and longevity of Treg-based therapies. Although this approach does not directly regenerate β-cells, it may preserve existing insulin-producing cells and enhance the effectiveness of other regenerative treatments. While still largely in the experimental phase, thymic regulatory T cell therapy offers a promising avenue for long-term immune-based intervention in autoimmune diabetes.

Methods of Stem Cell Delivery

The therapeutic efficacy of stem cell–based interventions in diabetes and other chronic disorders depends not only on the type of stem cells used but also on the method of their delivery. An optimal delivery strategy ensures maximum cell survival, effective homing to the target tissue, functional integration, and minimal adverse effects. Several delivery routes have been developed and evaluated in preclinical and clinical studies, each with distinct advantages and limitations.

1. Systemic (Intravenous) Delivery

Description:

In systemic delivery, stem cells are administered through intravenous infusion, allowing them to circulate throughout the bloodstream and migrate toward injured or inflamed tissues via chemotactic signals.

Advantages:

This method is minimally invasive, technically simple, and well tolerated by patients. It enables widespread distribution of cells, making it suitable for systemic diseases.

Limitations:

A major drawback is the low efficiency of cell homing to the target organ. A significant proportion of infused cells become trapped in non-target organs such as the lungs, liver, and spleen, reducing therapeutic effectiveness.

Applications:

Intravenous delivery is commonly used in conditions involving diffuse tissue damage or immune dysregulation, such as diabetes mellitus, autoimmune disorders, and inflammatory diseases, where immunomodulatory effects are desired.

2. Local (Direct) Injection

Description:

In this approach, stem cells are injected directly into the affected tissue or organ, such as the pancreas or myocardium.

Advantages:

Direct injection allows precise delivery of stem cells to the target site, significantly increasing local cell concentration and therapeutic potential.

Limitations:

The technique requires accurate placement and may involve surgical or image-guided procedures, which carry procedural risks.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Applications:
This method is preferred for localized tissue damage, including direct delivery of stem cells to pancreatic tissue in diabetes or to cardiac muscle following myocardial infarction.

3. Intra-arterial Delivery

Description:
Stem cells are infused into an artery supplying the target organ, ensuring directed delivery through the arterial circulation.

Advantages:
This approach enhances cell localization and improves delivery efficiency compared to systemic infusion.

Limitations:
Potential risks include vascular obstruction, embolism, and ischemic complications if cell aggregation occurs.

Applications:
Intra-arterial delivery has been investigated in neurological disorders, cardiovascular diseases, and targeted organ regeneration studies.

4. Intraperitoneal Delivery

Description:
In this method, stem cells are injected into the peritoneal cavity, allowing absorption through the peritoneal membrane.

Advantages:
The technique is relatively simple and enables broad cell distribution within the abdominal region.

Limitations:
Cell targeting is less precise, and therapeutic outcomes may be inconsistent due to variable cell migration.

Applications:
Intraperitoneal delivery is frequently used in experimental and preclinical studies, particularly for systemic metabolic and inflammatory disorders.

5. Scaffold-Based Delivery

Description:
Stem cells are seeded onto biocompatible scaffolds or embedded within hydrogels before transplantation.

Advantages:
Scaffolds provide structural support, enhance cell survival, promote differentiation, and facilitate vascular integration.

Limitations:
This method is technically complex, costly, and requires careful material selection and manufacturing standards.

Applications:
Scaffold-based delivery is extensively used in tissue engineering, pancreatic islet regeneration, and advanced regenerative medicine strategies.

6. Encapsulation Techniques

Description:
Stem cells or insulin-producing cells are encapsulated within semi-permeable biomaterials that allow nutrient and oxygen exchange while shielding cells from immune attack.

Advantages:
Encapsulation protects transplanted cells from immune rejection without the need for systemic immunosuppression.

Applications:
This technique is particularly valuable in diabetes therapy, where encapsulated pancreatic β-cells can secrete insulin while remaining immune-protected.

Preclinical and Clinical Studies

Extensive preclinical studies have laid the foundation for stem cell–based diabetes therapies. These investigations focus on evaluating cell survival, differentiation potential, insulin secretion, immune response, and safety before clinical translation.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Types of Stem Cells Used in Preclinical Studies

Embryonic Stem Cells (ESCs):

ESCs have been successfully differentiated into pancreatic β-like cells capable of glucose-responsive insulin secretion, demonstrating strong regenerative potential.

Induced Pluripotent Stem Cells (iPSCs):

Derived from adult somatic cells, iPSCs reduce ethical concerns and immune rejection risks while offering patient-specific therapeutic options.

Mesenchymal Stem Cells (MSCs):

Found in bone marrow, adipose tissue, and umbilical cord tissue, MSCs protect residual β-cells, suppress inflammation, and improve insulin sensitivity.

Hematopoietic and Pancreatic Progenitor Cells:

These cells contribute to pancreatic tissue regeneration and immune system modulation, supporting β-cell recovery.

Animal Models Used in Diabetes Research

Animal models play a critical role in evaluating the safety and efficacy of stem cell therapies for diabetes.

1. Streptozotocin-Induced Diabetes Model

Type: Chemically induced model

Mechanism: Streptozotocin selectively destroys pancreatic β-cells, leading to insulin deficiency and hyperglycemia.

Application: Widely used to model Type 1 diabetes.

Purpose: To assess whether transplanted stem cells can restore insulin production and normalize blood glucose levels. Studies have shown that transplantation of ESC- or iPSC-derived β-like cells significantly reduces hyperglycemia in diabetic rodents.

2. Alloxan-Induced Diabetes Model

Type: Chemically induced model

Mechanism: Alloxan induces oxidative stress in pancreatic β-cells, resulting in insulin deficiency.

Applications: Early-stage drug screening and stem cell therapy evaluation in Type 1 diabetes research.

Advantages: Economical and easy to establish.

Limitations: Glycemic variability and lower stability compared to the streptozotocin model.

Conclusion

The success of stem cell–based therapy for diabetes relies on selecting appropriate cell types, delivery methods, and experimental models. Advances in delivery technologies and preclinical research continue to improve therapeutic outcomes. Although promising, further optimization and large-scale clinical trials are essential to establish standardized protocols and ensure long-term safety and efficacy.

3. Non-Obese Diabetic (NOD) Mouse Model

Type: Autoimmune and genetic model

The non-obese diabetic (NOD) mouse is a well-established experimental model that closely resembles human Type 1 diabetes mellitus. In this model, diabetes develops spontaneously due to autoimmune destruction of pancreatic β-cells without the need for chemical induction. The disease progression involves infiltration of autoreactive T lymphocytes into pancreatic islets, leading to progressive β-cell loss and insulin deficiency.

Applications:

The NOD mouse model is extensively used to investigate immunomodulatory strategies in diabetes therapy. It is particularly valuable for assessing the immune-regulating properties of mesenchymal stem cells (MSCs), regulatory T cells, and other stem cell populations. Studies in NOD mice have demonstrated that MSC therapy can protect β-cells, reduce inflammatory cytokine production, and suppress autoimmune responses, thereby delaying or preventing the onset of diabetes.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

4. High-Fat Diet (HFD)–Induced Mouse Model

Type: Diet-induced Type 2 diabetes model

In this model, animals are fed a high-fat diet over an extended period, resulting in obesity, insulin resistance, and moderate hyperglycemia. The metabolic abnormalities observed in HFD-fed mice closely resemble the pathophysiological features of human Type 2 diabetes, including chronic inflammation and impaired insulin signaling.

Applications:

This model is widely used to evaluate the effects of stem cell therapy on metabolic regulation. Studies have shown that administration of MSCs in HFD-fed mice improves insulin sensitivity, reduces systemic inflammation, and enhances glucose tolerance. The HFD model is particularly useful for assessing combined metabolic and regenerative effects of stem cell–based interventions.

5. Large Animal Models (Pig, Dog, Non-Human Primates)

Use:

Large animal models are employed after successful rodent studies to evaluate the safety, scalability, and translational potential of stem cell therapies prior to human clinical trials.

Advantages:

These models possess physiological and anatomical characteristics more closely resembling humans, particularly in terms of pancreatic structure, immune responses, and metabolic regulation.

Examples:

Transplantation of human iPSC-derived pancreatic progenitor cells into diabetic pigs has demonstrated functional insulin secretion and improved glycemic control, supporting the feasibility of large-scale stem cell transplantation.

Clinical Studies of Stem Cell Therapy in Diabetes

Preclinical investigations have consistently demonstrated promising outcomes for stem cell–based treatment of diabetes. Building upon these findings, numerous clinical trials have been conducted worldwide to evaluate safety, efficacy, and long-term outcomes in human patients. The primary objectives of these trials include restoration of insulin-producing β-cells, improvement of glucose regulation, and reduction in dependence on exogenous insulin therapy.

Types of Stem Cells Used in Clinical Studies

Mesenchymal Stem Cells (MSCs):

Derived from bone marrow, adipose tissue, or umbilical cord tissue, MSCs exhibit potent immunomodulatory and anti-inflammatory properties. They enhance insulin sensitivity, preserve residual β-cell function, and reduce autoimmune-mediated damage.

Embryonic Stem Cells (ESCs):

ESCs differentiated into insulin-producing β-like cells have been evaluated in early-phase clinical trials for Type 1 diabetes, demonstrating the potential for β-cell replacement.

Induced Pluripotent Stem Cells (iPSCs):

Generated by reprogramming adult somatic cells, iPSCs enable patient-specific β-cell production while minimizing ethical concerns and immune rejection risks.

Hematopoietic Stem Cells (HSCs):

Used in selected studies to reset the immune system and suppress autoimmune destruction of β-cells in Type 1 diabetes.

Challenges and Limitations of Stem Cell Therapy

Major Challenges

Stem cell–based therapy for diabetes faces several scientific, technical, and regulatory challenges. Differentiating stem cells into fully mature, glucose-responsive β-cells remains difficult. Post-transplant engraftment and long-term survival of transplanted cells are often limited, and immune rejection continues to be a significant concern.

Safety issues include the risk of teratoma or tumor formation, particularly with pluripotent stem cells. Achieving sustained insulin secretion and long-term glycemic control remains challenging, and standardized protocols for stem cell sourcing, processing, and delivery are still lacking. Ethical concerns, high treatment costs, regulatory barriers, and variability in stem cell quality further complicate clinical translation.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Additional challenges include difficulty in targeted pancreatic delivery, large-scale production of clinical-grade stem cells, monitoring transplanted cells in vivo, and limited understanding of the precise mechanisms underlying stem cell–mediated regeneration.

Limitations of Stem Cell Therapy

Despite significant progress, stem cell therapy has notable limitations. Regeneration of pancreatic islet cells is often incomplete, and β-cells derived from transplanted stem cells may exhibit limited lifespan or insufficient insulin production. Some patients experience disease relapse, necessitating repeated treatments.

Long-term safety data in humans are limited, and the effects of stem cell therapy on other organ systems remain unclear. Treatment outcomes vary widely among patients, and accessibility is restricted due to high costs and infrastructure requirements. Immunosuppression increases the risk of infection and inflammation, while animal models do not always accurately predict human responses.

Role of the Pharmacist in Stem Cell Therapy

1. Research and Development

Pharmacists play a critical role in stem cell research by contributing to preclinical and clinical studies. Their expertise is essential in optimizing stem cell formulations, storage conditions, stability, and delivery systems, including injectable stem cell suspensions and encapsulated β-cell products.

2. Quality Control and Good Manufacturing Practices (GMP)

Pharmacists ensure that stem cell products meet stringent quality, purity, safety, and consistency standards. They oversee compliance with Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) guidelines to ensure safe clinical application.

3. Regulatory and Ethical Oversight

Pharmacists assist in regulatory documentation, protocol submission, and ethical compliance. Their involvement ensures transparency, patient safety, and adherence to national and international regulatory frameworks governing stem cell–based therapies.

Conclusion

Stem cell therapy represents a transformative and highly promising approach for the treatment of diabetes mellitus. While significant progress has been made in preclinical and clinical research, numerous challenges must be addressed before widespread clinical adoption can be achieved. Continued interdisciplinary collaboration, technological advancement, and regulatory harmonization are essential for translating stem cell therapy into a safe, effective, and accessible treatment option for diabetic patients.

Expanded Role of Pharmacists in Stem Cell Therapy for Diabetes

4. Clinical Role and Patient Care

In clinical practice, pharmacists collaborate closely with physicians and multidisciplinary healthcare teams to ensure the safe and effective administration of stem cell–based therapies. Their responsibilities include verifying appropriate dosing, timing, and routes of administration, as well as monitoring potential drug–cell interactions. Pharmacists also assist in managing supportive medications, such as immunosuppressive agents, and contribute to individualized treatment planning for patients undergoing stem cell therapy.

5. Pharmacovigilance and Safety Monitoring

Pharmacists play a vital role in pharmacovigilance by monitoring, documenting, and reporting adverse events associated with stem cell therapy. These include immunological reactions, inflammatory responses, infections, and long-term safety concerns. By contributing to post-treatment surveillance and adverse event reporting systems, pharmacists support the optimization of therapeutic protocols and the generation of long-term safety data essential for regulatory approval and clinical acceptance.

6. Patient Education and Counseling

Patient education is a critical component of stem cell–based diabetes management. Pharmacists provide clear and evidence-based information regarding the potential benefits, risks, limitations, and realistic expectations of stem cell therapy. Through counseling, pharmacists help patients understand treatment procedures, adherence requirements, possible side effects, and the importance of follow-up care, thereby promoting informed decision-making and improved treatment compliance.

7. Future Role in Personalized Medicine

With advances in regenerative medicine and biotechnology, pharmacists are expected to assume an increasingly important role in personalized therapy. This includes participation in the development and clinical application of patient-specific stem cell–derived insulin-producing cells. Pharmacists will contribute to tailoring therapies based on individual genetic profiles, disease severity, and immune status, thereby enhancing therapeutic efficacy and minimizing adverse outcomes.

REFERENCES

[1]. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Diabetes: An Old Disease, a New Insight. 2012;1–1.
[2]. Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.
[3]. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
[4]. Alison MR, Poulsom R, Forbes S, Wright NA. An introduction to stem cells. J Pathol. 2002;197(4):419–423.
[5]. Lajtha LG. Stem cell concepts. Differentiation. 1979;14(1–3):23–33.
[6]. Slack JM. What is a stem cell? Wiley Interdiscip Rev Dev Biol. 2018;7(5):e323.
[7]. McCulloch EA, Till JE. Perspectives on the properties of stem cells. Nat Med. 2005;11(10):1026–1028.
[8]. El-Badawy A, El-Badri N. Clinical efficacy of stem cell therapy for diabetes mellitus: A meta-analysis. PLoS One. 2016;11(4):e0151938.
[9]. Zhang Y, Chen W, Feng B, Cao H. Clinical efficacy and safety of stem cell therapy for diabetes mellitus: A systematic review and meta-analysis. Aging Dis. 2020;11(1):141–153.
[10]. Zuo DB, Wang CH, Sang M, et al. Stem cell therapy for diabetes: Advances, prospects, and challenges. World J Diabetes. 2025;16(7):107344.
[11]. Pires IG, Souza JA, Bisneto AVM, et al. Clinical efficacy of stem-cell therapy on diabetes mellitus: A systematic review and meta-analysis. Transpl Immunol. 2022;75:101740.
[12]. Hussain MA, Theise ND. Stem-cell therapy for diabetes mellitus. Lancet. 2004;364(9429):203–205.
[13]. Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020;10(4):174–188.
[14]. Saberzadeh-Ardestani B, Karamzadeh R, Basiri M, et al. Type 1 diabetes mellitus: Cellular and molecular pathophysiology. Cell J. 2018;20(3):294–301.
[15]. Aamodt KI, Powers AC. Pathophysiology, presentation, and classification of Type 1 diabetes. Diabetes Obes Metab. 2025;27:15–27.
[16]. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgrad Med J. 2016;92(1084):63–69.
[17]. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275.
[18]. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg. 2003;58(6):335–341.
[19]. Kohei KA. Pathophysiology of type 2 diabetes and its treatment policy. JMAJ. 2010;53(1):41–46.
[20]. Zang L, Hao H, Liu J, et al. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:36.
[21]. Vija L, Farge D, Gautier JF, et al. Mesenchymal stem cells: Perspectives for type 1 diabetes. Diabetes Metab. 2009;35(2):85–93.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

[22]. Stepniewski J, Kachamakova-Trojanowska N, Ogrocki D, et al. Induced pluripotent stem cells as a model for diabetes investigation. Sci Rep. 2015;5:8597.

[23]. Bose B, Shenoy SP, Konda S, Wangikar P. Human embryonic stem cell differentiation into insulin-secreting β-cells. Cell Biol Int. 2012;36(11):1013–1020.

[24]. Lopes L, Setia O, Aurshina A, et al. Stem cell therapy for diabetic foot ulcers. Stem Cell Res Ther. 2018;9:188.

[25]. De Klerk E, Hebrok M. Stem cell–based clinical trials for diabetes mellitus. Front Endocrinol. 2021;12:631463.

[26]. Ghoneim MA, Gabr MM, El-Halawani SM, Refaie AF. Current status of stem cell therapy for type 1 diabetes. Stem Cell Res Ther. 2024;15:23.

[27]. Lu J, Cheng H, Chen K, Zhang F. From bench to bedside: Future prospects in stem cell therapy for diabetes. J Transl Med.